The National Institute for Health and Care Excellence (NICE) have issued a position statement on the use of the EQ-5D-5L valuation set. The statement recommends not using the 5L valuation set for evidence submissions to NICE that use cost-utility analyses. Preference should be given to the EQ-5D-3L valuation set. The full statement gives more detail on the decision from the NICE Decision Support Unit.
The National Institute for Health and Care Excellence (NICE) have published guidance on Collagenase clostridium histolyticum for treating Dupuytren’s contracture [TA459]. The treatment is recommended only under specific circumstances while an on-going trial is conducted. HERU staff contributed to the evidence for the development of the guidance.
The Decision Support Unit (DSU) at the National Institute for Health and Care Excellence (NICE) have produced a Technical Support Document on the use of partitioned survival analysis as a decision modelling tool in health technology assessments. The report contains a description of partitioned survival analysis and how if differs from other models, a review of it’s use in recent NICE Technology Appraisals of cancer treatments, a critique of the model and a series of recommendations.
The DSU is a collaboration between the Universities of Sheffield, York and Leicester that is commissioned by NICE to provide a research and training resource to support the Institute’s Technology Appraisal Programme.
Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. 2017 [Available from http://www.nicedsu.org.uk%5D